Clinical Trials Logo
  1. Home
  2. Immunoglobulin A Nephropathy
  3. NCT02384317

Open-Label Study to Evaluate Safety and Efficacy of CCX168 in Subjects With IGA Nephropathy on Stable RAAS Blockade

Immunoglobulin A Nephropathy Clinical Trial

Official title:
An Open-Label Phase 2 Study to Evaluate the Safety and Efficacy of CCX168 in Subjects With Immunoglobulin A Nephropathy on Stable RAAS Blockade

Clinical Trial Summary

The primary safety objective of this study is to evaluate the safety and tolerability of CCX168 in subjects with IgAN on background supportive therapy with a maximally tolerated dose of RAAS blockade. The primary efficacy objective is to evaluate the efficacy of CCX168 based on an improvement in proteinuria.

Clinical Trial Description

n/a

Study Design

Related Conditions & MeSH terms

Clinical Trial Details
NCT number NCT02384317
Study type Interventional
Source ChemoCentryx
Contact
Status Completed
Phase Phase 2
Start date March 27, 2015
Completion date June 1, 2018
View Details
See also
  Status Clinical Trial Phase
Completed NCT03719443 - First in Human Study to Assess Safety of VIS649 in Healthy Subjects Phase 1
Enrolling by invitation NCT05132621 - The Genital Tract Microflora in Women With Systemic Lupus Erythematosus (SLE) and Immunoglobulin A (IgA) Nephropathy.
Recruiting NCT05856760 - A Study to Investigate Safety and Effect of Sparsentan in Combination With SGLT2 Inhibition in Participants With IgAN Phase 2
Recruiting NCT04662723 - Multicentre Clinical Study to Evaluate the Effect of Personalized Therapy on Patients With Immunoglobulin A Nephropathy. Phase 4
Recruiting NCT06291376 - Study of Ravulizumab in Immunoglobulin A Nephropathy (IgAN) Phase 3
Recruiting NCT05732402 - An Open-label Study of Povetacicept (ALPN-303) in Autoimmune Kidney Diseases Phase 1/Phase 2
Active, not recruiting NCT05248646 - Visionary Study: Phase 3 Trial of Sibeprenlimab in Immunoglobulin A Nephropathy (IgAN) Phase 3
Completed NCT01838239 - Development of a Metabolic Assessment Tool for Chronic Kidney Disease N/A
Recruiting NCT05852938 - A Study of BION-1301 in Adults With IgA Nephropathy Phase 3
Recruiting NCT05834738 - Randomized, Double-blind, Placebo-controlled, Crossover Study of Atrasentan in Subjects With IgA Nephropathy Phase 2
Completed NCT04287985 - Safety and Efficacy Study of VIS649 for IgA Nephropathy Phase 2
Recruiting NCT05097989 - Study of ALXN2050 in Proliferative Lupus Nephritis (LN) or Immunoglobulin A Nephropathy (IgAN) Phase 2
Completed NCT05200871 - Humanistic Burden of (FSGS) Focal Segmental Glomerulosclerosis and IgAN (Immunoglobulin A Nephropathy)
Terminated NCT05162066 - Study to Evaluate the Safety, Tolerability of BCX9930 in Participants With Either Complement 3 Glomerulopathy (C3G), Immunoglobulin A Nephropathy (IgAN), or Primary Membranous Nephropathy (PMN) Phase 2
Active, not recruiting NCT04573920 - Atrasentan in Patients With Proteinuric Glomerular Diseases Phase 2
Withdrawn NCT02605525 - Efficacy and Safety of SM101 in the Treatment of IgA Nephropathy Phase 2
Recruiting NCT04564339 - Study of Ravulizumab in Proliferative Lupus Nephritis (LN) or Immunoglobulin A Nephropathy (IgAN) Phase 2
Active, not recruiting NCT04573478 - Atrasentan in Patients With IgA Nephropathy Phase 3
Active, not recruiting NCT03762850 - A Study of the Effect and Safety of Sparsentan in the Treatment of Patients With IgA Nephropathy Phase 3
Active, not recruiting NCT04663204 - A Study of the Safety and Activity of Sparsentan for the Treatment of Incident Patients With Immunoglobulin A Nephropathy Phase 2